Mutual of America Capital Management LLC Has $14.23 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mutual of America Capital Management LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,535 shares of the biopharmaceutical company’s stock after selling 409 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $14,229,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quent Capital LLC grew its holdings in Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 19 shares during the period. Acadian Asset Management LLC increased its holdings in Regeneron Pharmaceuticals by 37.2% in the first quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after purchasing an additional 16,856 shares during the last quarter. Jacobi Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 1.8% in the first quarter. Jacobi Capital Management LLC now owns 1,139 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 20 shares during the period. Covestor Ltd boosted its holdings in Regeneron Pharmaceuticals by 7.4% during the first quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 14 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Regeneron Pharmaceuticals by 17.5% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock worth $6,660,000 after buying an additional 1,030 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 3.3 %

REGN stock opened at $756.81 on Friday. The company has a market cap of $83.17 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $753.69 and a twelve month high of $1,211.20. The business has a 50 day moving average price of $985.21 and a two-hundred day moving average price of $1,033.97. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Analyst Ratings Changes

Several brokerages have commented on REGN. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday. They issued an “outperform” rating and a $1,150.00 price target for the company. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.